JumpStart Ventures Invests $250,000 in Thermalin Diabetes Inc.
03/29/2010
"Over the next 20 years, worldwide insulin sales are expected to grow from $12 billion to $54 billion, JumpStart Ventures partner Ted Frank told Crain's Cleveland Business. "That growth, combined with the medical community's interest in insulin with higher performance, fewer side effects, and storage flexibility, position Thermalin's pipeline to be in high demand."
Thermalin will use the funds to validate its insulin analogs' characteristics, locate a manufacturer, and proceed in the investigational drug process with the FDA.
The company's products include a faster meal-time insulin that is expected to reduce long-term side effects. The insulin can also be stored at higher temperatures, which would make transport and delivery easier.
Project Announcements
GE Appliances Expands Jefferson County, Kentucky, Operations
06/30/2025
ValorFlex Packaging Plans Bowling Green, Kentucky, Production Operations
06/30/2025
Neuro.io Plans Terrebonne Parish, Louisiana, Operations
06/30/2025
Germany-Based MTU Maintenance Expands Fort Worth, Texas, MRO Operations
06/30/2025
Cascade Die Casting Group Expands High Point, North Carolina, Manufacturing Operations
06/30/2025
BuildOps Plans Raleigh, North Carolina, Operations
06/30/2025
Most Read
-
20th Annual Area Development Gold and Silver Shovel Awards
Q2 2025
-
First Person: Joe Capes, CEO, LiquidStack
Q2 2025
-
The Legal Limits of DEI in Incentives Agreements, Hiring, and Contracting
Q2 2025
-
From Silicon to Server: Mapping the Data Center Supply Chain
Q2 2025
-
39th Annual Corporate & 21st Annual Consultants Surveys: What Business Leaders and Consultants Are Saying About Site Selection
Q1 2025
-
Rethinking Life Sciences Site Selection in a Resilient and Dynamic Market
Q2 2025
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024